ella zeldich
  • Title Instructor, Abraham Lab
  • Education MS: Medical Sciences, Tel Aviv University, Israel
    PhD in Oral Biology and Physiology and Pharmacology, from Tel Aviv University, Israel
  • Office K112
  • Phone 617-358-4184
  • Area of Interest Alzheimer’s disease and aging, Neuroprotection, Klotho transcriptional regulation

I joined Dr. Abraham’s lab as a postdoctoral associate in 2011. Since then I have been studying the roles the anti-aging protein Klotho and the Amyloid Precursor Protein (APP) in the brain under conditions associated with Alzheimer’s disease (AD) and Multiple Sclerosis (MS). I have been investigating the neuroprotective properties of Klotho under oxidative stress conditions in primary neurons and we identified the crucial involvement of the members of the redox system in Klotho-induced neuroprotection. I also have been studying the link between Klotho and myelin, and we showed recently the re-myelinating effect of Klotho, a finding that has a clinical importance to MS. In order to therapeutically exploit the neuroprotective properties of Klotho, we conduct translational studies through the screening and testing of Klotho enhancing compounds in in vitro, ex-vivo and in vivo systems.

Another research focus is the reduction of the accumulation of neurotoxic amyloid beta (Abeta), which is the main component of the amyloid plaques found in the brains of Alzheimer patients. This research topic is based on the regulation of APP phosphorylation and processing by small molecules that subsequently leads to a decreases production of amyloid beta. We identified recently a new signaling pathway involved in the regulation of APP processing that presents a novel therapeutic approach to prevent or treat the pathogenesis associated with AD.

View all people